Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)

Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)

US Patent 11642395 · Granted May 9, 2023

Estimated economic value: $887,089,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Catalytic de-crosslinking of samples for in situ analysis2025
Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containin2025
Compositions and methods for targeted masking of autofluorescence2025
Nucleic acid assays using click chemistry bioconjugation2025
Sex toy2024
Methods for extracting milk protein from expired or spoiled milk2023
Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-agi2022
Methods of treating diseases associated with fibrosis using modified FGF-21 poly2022
Compositions and methods for selectively depleting senescent cells2020
Automated immunoanalyzer system for performing diagnostic assays for allergies a2020
Methods of treating diseases associated with fibrosis using modified FGF-21 poly2019
Therapeutic uses of modified FGF-21 polypeptides2019